Recent

% | $
Quotes you view appear here for quick access.

IntelliPharmaCeutics International Inc. Message Board

  • wimuskyfisherman wimuskyfisherman Jul 24, 2014 10:04 AM Flag

    Purdue Targiniq ER

    Looks like Purdue Targiniq ER was approved yesterday. Has some abuse deterrence but the company that brings out the "truly" abuse deterrent drug will win in the end:

    Today, the U.S. Food and Drug Administration approved Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended-release tablets), an extended-release/long-acting (ER/LA) opioid analgesic to treat pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Targiniq ER is the second ER/LA opioid analgesic with FDA-approved labeling describing the product’s abuse-deterrent properties consistentwith the FDA’s 2013 draft guidance for industry, Abuse-Deterrent Opioids – Evaluation and Labeling.

    Targiniq ER has properties that are expected to deter, but not totally prevent, abuse of the drug by snorting and injection. When crushed and snorted, or crushed, dissolved and injected, the naloxone in Targiniq ER blocks the euphoric effects of oxycodone, making it less liked by abusers than oxycodone alone. Naloxone is a medication that is commonly used to reverse the effects of opioid overdose. Targiniq ER can still be abused, including when taken orally (by mouth), which is currently the most common way oxycodone is abused. It is important to note that taking too much Targiniq ER for purposes of abuse or by accident, can cause an overdose that can result in death.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • wimusky....good info. thanks ! not only is Rexista more abuse deterrent they also have the capability to make it single does time released. I dont think Purdues or Tevas has that capability. I hope the company releases their next set of data soon. and gets on the way to phase 2. I think they will still need to partner to do the trails unless thats part of what the shelf is for? to do their own trials?... personally I think the money would be better spent to open their own manufacturing because even if they did their own phase II they still cant import a class 2 drug. they would need something here in the US to get in. unless they will just target overseas. IPCI is still going to be a game changer here

      • 1 Reply to samsa1
      • Samsa- I am hearing what you are saying. I really used to think the big payday would be in Rexista. It still may be, but now I am wondering if manufacturing is their real goal? When you add up the annual numbers on all the generics in their pipeline, you really see the potential. That is a very long range plan, but several years down the road they could be manufacturing a handful of generics themselves and profits would be substantial.

 
IPCI
3.54+0.08(+2.31%)12:33 PMEDT